BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 11298092)

  • 21. Effect of 1 alpha-hydroxyvitamin D3 on serum levels of thyroid hormones in hyperthyroid patients with untreated Graves' disease.
    Kawakami-Tani T; Fukawa E; Tanaka H; Abe Y; Makino I
    Metabolism; 1997 Oct; 46(10):1184-8. PubMed ID: 9322804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
    Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
    Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK; Yoo WS; Kim DW; Chung HK
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Differential Effects of Propylthiouracil and Methimazole as Graves' Disease Treatment on Vascular Atherosclerosis Markers: A Randomized Clinical Trial.
    Wisnu W; Alwi I; Nafrialdi N; Harimurti K; Pemayun TGD; Jusman SWA; Santoso DIS; Harahap AR; Suwarto S; Subekti I
    Front Endocrinol (Lausanne); 2021; 12():796194. PubMed ID: 34987480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T4 suppression test involving 24-hour thyroidal 131I uptake in patients with Graves' disease compared to the T3 suppression test.
    Kobayashi I; Ishii H; Mori M; Kobayashi S
    Endocrinol Jpn; 1984 Jun; 31(3):263-70. PubMed ID: 6548699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro immunoreactivity to propylthiouracil, methimazole, and carbimazole in patients with Graves' disease: a possible cause of antithyroid drug-induced agranulocytosis.
    Wall JR; Fang SL; Kuroki T; Ingbar SH; Braverman LE
    J Clin Endocrinol Metab; 1984 May; 58(5):868-72. PubMed ID: 6200492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence of and Risk Factors for Neonatal Hypothyroidism Among Women with Graves' Disease Treated with Antithyroid Drugs Until Delivery.
    Yoshihara A; Noh JY; Inoue K; Watanabe N; Fukushita M; Matsumoto M; Suzuki N; Suzuki A; Kinoshita A; Yoshimura R; Aida A; Imai H; Hiruma S; Sugino K; Ito K
    Thyroid; 2023 Mar; 33(3):373-379. PubMed ID: 36680759
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism.
    Sato S; Noh JY; Sato S; Suzuki M; Yasuda S; Matsumoto M; Kunii Y; Mukasa K; Sugino K; Ito K; Nagataki S; Taniyama M
    Thyroid; 2015 Jan; 25(1):43-50. PubMed ID: 25178068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease.
    Hancock LD; Tuttle RM; LeMar H; Bauman J; Patience T
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):425-30. PubMed ID: 9404440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs.
    Benker G; Reinwein D; Kahaly G; Tegler L; Alexander WD; Fassbinder J; Hirche H
    Clin Endocrinol (Oxf); 1998 Oct; 49(4):451-7. PubMed ID: 9876342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease.
    Takata K; Amino N; Kubota S; Sasaki I; Nishihara E; Kudo T; Ito M; Fukata S; Miyauchi A
    Clin Endocrinol (Oxf); 2010 Jun; 72(6):845-50. PubMed ID: 19912243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Remission of Graves' disease is not related to early restoration of euthyroidism with high-dose methimazole therapy.
    Kruljac I; Solter D; Vrkljan AM; Solter M
    Endocr Res; 2015; 40(1):25-8. PubMed ID: 24833206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to methimazole in Graves' disease. The European Multicenter Study Group.
    Benker G; Vitti P; Kahaly G; Raue F; Tegler L; Hirche H; Reinwein D
    Clin Endocrinol (Oxf); 1995 Sep; 43(3):257-63. PubMed ID: 7586593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Substituting Potassium Iodide for Methimazole as the Treatment for Graves' Disease During the First Trimester May Reduce the Incidence of Congenital Anomalies: A Retrospective Study at a Single Medical Institution in Japan.
    Yoshihara A; Noh JY; Watanabe N; Mukasa K; Ohye H; Suzuki M; Matsumoto M; Kunii Y; Suzuki N; Kameda T; Iwaku K; Kobayashi S; Sugino K; Ito K
    Thyroid; 2015 Oct; 25(10):1155-61. PubMed ID: 26222916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of methimazole and propylthiouracil in the management of children and adolescents with Graves' disease: efficacy and adverse reactions during initial treatment and long-term outcome.
    Sato H; Minagawa M; Sasaki N; Sugihara S; Kazukawa I; Minamitani K; Wataki K; Konda S; Inomata H; Sanayama K; Kohno Y
    J Pediatr Endocrinol Metab; 2011; 24(5-6):257-63. PubMed ID: 21823520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effective methimazole dose for childhood Graves' disease and use of free triiodothyronine combined with concurrent thyroid-stimulating hormone level to identify mild hyperthyroidism and delayed pituitary recovery.
    Slyper AH; Wyatt D; Boudreau C
    J Pediatr Endocrinol Metab; 2005 Jun; 18(6):597-602. PubMed ID: 16042328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of methylmercaptoimidazole (MMI), propylthiouracil (PTU), potassium perchlorate (KClO4) and potassium iodide (KI) on the serum concentrations of thyrotrophin (TSH) and thyroid hormones in the rat.
    Männistö PT; Ranta T; Leppäluoto J
    Acta Endocrinol (Copenh); 1979 Jun; 91(2):271-81. PubMed ID: 111448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of colestipol in the treatment of hyperthyroidism.
    Hagag P; Nissenbaum H; Weiss M
    J Endocrinol Invest; 1998 Dec; 21(11):725-31. PubMed ID: 9972670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of hypothyroidism on hypothalamic release of thyrotropin-releasing hormone in rats.
    Rondeel JM; de Greef WJ; Klootwijk W; Visser TJ
    Endocrinology; 1992 Feb; 130(2):651-6. PubMed ID: 1733713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The evolution of Graves' ophthalmopathy during treatment with antithyroid drug alone and combined with triiodothyronine.
    Bromberg N; Romaldini JH; Werner RS; Sgarbi JA; Werner MC
    J Endocrinol Invest; 1992 Mar; 15(3):191-5. PubMed ID: 1624679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.